Welcome to our dedicated page for Relay Therapeutics SEC filings (Ticker: RLAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relay Therapeutics, Inc. (Nasdaq: RLAY) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a clinical-stage precision medicine company focused on small molecule therapies for cancer and genetic disease, Relay Therapeutics uses these filings to report on its financial condition, governance and material developments related to programs such as its PI3Kα inhibitor RLY-2608, also known as zovegalisib.
Among the most frequently referenced documents are current reports on Form 8-K, which Relay Therapeutics files to announce events such as quarterly financial results and changes to its Board of Directors. For example, 8-K filings describe the release of earnings press statements for specific quarters and the appointment of new independent directors, along with related committee assignments and equity compensation terms.
Investors researching RLAY can also use this page to locate periodic reports such as Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which the company cites in its risk factor discussions within press releases. These filings typically contain detailed information on research and development expenses, general and administrative costs, net losses, and risk factors associated with developing clinical-stage programs like RLY-2608 and other pipeline assets.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as results of operations, liquidity, and governance changes. Real-time updates from the EDGAR system ensure that new Relay Therapeutics filings, including future Forms 10-K, 10-Q, 8-K and beneficial ownership or insider transaction reports like Form 4, appear promptly on this page.
By combining the raw SEC documents with AI-generated overviews, this filings page offers a structured view into Relay Therapeutics’ regulatory history, financial reporting and significant corporate events relevant to the RLAY stock.
Relay Therapeutics, Inc. reported that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its drug candidate zovegalisib (RLY-2608) in combination with fulvestrant. This designation covers adults with PIK3CA mutant HR+/HER2- locally advanced or metastatic breast cancer that has recurred or progressed after treatment with a CDK4/6 inhibitor.
Relay Therapeutics President of R&D Donald A. Bergstrom reported automatic sales of common stock to cover tax withholding on recently vested RSUs. On January 27, 2026, 18,895 shares were sold at
The footnotes state these transactions were executed without his discretion under company policies when 59,550 and 9,072 RSUs vested. After these transactions, he beneficially owned 420,047 shares, including 20,049 shares underlying RSUs.
Relay Therapeutics officer reports ESPP purchase and tax sales. Chief Corporate Development Officer Peter Rahmer bought 994 shares of Relay Therapeutics common stock on December 31, 2025 under the 2020 Employee Stock Purchase Plan at $2.99 per share, a transaction the company notes is voluntarily reported.
On January 27, 2026 he sold 11,684 shares at $7.62 per share, and on January 28, 2026 he sold 1,354 shares at $8.45 per share. Footnotes state both sales were made only to cover income tax withholding on vesting RSUs, with no discretion over the sales. After these transactions, he beneficially owned 276,610 shares, including shares underlying RSUs.
Relay Therapeutics Chief Financial Officer Thomas Catinazzo reported automatic share sales tied to restricted stock unit (RSU) vesting. On January 27, 2026, he sold 13,820 shares of common stock at $7.62 per share, and on January 28, 2026, he sold 1,695 shares at $8.45 per share.
Footnotes state both transactions were sales of shares to cover income tax withholding obligations upon the vesting of 42,394 and 5,724 RSUs, and that he had no discretion over the sales under company policies. After these transactions, he beneficially owned 250,996 and then 249,301 shares, including shares underlying RSUs.
Relay Therapeutics, Inc. reported that Donald A. Bergstrom, its President of R&D, received a grant of stock options on January 13, 2026. The award covers 575,000 stock options, each representing the right to buy one share of common stock at an exercise price of $7.94 per share. Following this grant, Bergstrom beneficially owns 575,000 derivative securities directly.
The options are designed to vest over time. According to the disclosure, the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, and each vesting date requires Bergstrom to continue his service with the company. This structure aligns the award with ongoing tenure and performance in his executive role.
Relay Therapeutics, Inc. reported an insider equity award for Chief Corporate Development Officer Peter Rahmer. On January 13, 2026, he received a stock option covering 475,000 shares of common stock at an exercise price of $7.94 per share.
According to the filing, the shares underlying this option vest in sixteen equal quarterly installments after January 13, 2026, contingent on his continued service with the company through each vesting date. Following this grant, Rahmer beneficially owned 475,000 derivative securities directly in the form of this stock option.
Relay Therapeutics, Inc. reported that President and CEO Sanjiv Patel received a stock option grant. On January 13, 2026, he was awarded an option to buy 1,450,000 shares of Relay Therapeutics common stock at an exercise price of $7.94 per share. The filing states that the shares underlying this option will vest in sixteen equal quarterly installments after January 13, 2026, so long as he continues to serve with the company through each vesting date. Following this grant, he beneficially owned 1,450,000 derivative securities directly.
Relay Therapeutics reported that its Chief Financial Officer, Thomas Catinazzo, received a new stock option grant. On 01/13/2026, he was awarded a stock option to buy 400,000 shares of common stock at $7.94 per share. After this grant, he beneficially owns 400,000 derivative securities directly.
The option shares will vest in sixteen equal quarterly installments after January 13, 2026, and each installment requires his continued service with the company through the applicable vesting date. This filing records the award and resulting beneficial ownership rather than any share sale.
Relay Therapeutics, Inc. President and CEO Sanjiv Patel reported both a share purchase and a sale of company stock. On December 31, 2025, he acquired 994 shares of common stock at $2.99 per share under the company’s 2020 Employee Stock Purchase Plan, a transaction described as exempt under Rule 16b-3 and voluntarily reported. On January 6, 2026, he sold 43,168 shares of common stock at $7.82 per share to cover income tax withholding obligations arising from the vesting of 136,854 restricted stock units on January 5, 2026, with no discretion over the sale terms.
After these transactions, he directly held 661,041 shares of common stock, which includes 136,854 shares underlying RSUs. The filing also reports 199,548 and 687,355 shares of common stock held indirectly in irrevocable family trusts with an independent trustee, for which Patel disclaims beneficial ownership.
Relay Therapeutics (RLAY) reported an insider equity award. A company director disclosed a stock option grant to buy 207,931 shares at an exercise price of $6.86 per share on November 4, 2025.
The option expires on November 3, 2035 and vests in 36 equal monthly installments after November 4, 2025, contingent on continued service. The filing indicates direct ownership of the derivative security.
FAQ
What is the current stock price of Relay Therapeutics (RLAY)?
What is the market cap of Relay Therapeutics (RLAY)?
